These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15725088)

  • 1. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning.
    Panse JP; Heimfeld S; Guthrie KA; Maris MB; Maloney DG; Baril BB; Little MT; Chauncey TR; Storer BE; Storb R; Sandmaier BM
    Br J Haematol; 2005 Mar; 128(5):659-67. PubMed ID: 15725088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
    Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S
    Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.
    Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Greimers R; Herens C; Fillet G; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):301-14. PubMed ID: 11983101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors.
    Petersen SL; Ryder LP; Björk P; Madsen HO; Heilmann C; Jacobsen N; Sengeløv H; Vindeløv LL
    Bone Marrow Transplant; 2003 Jul; 32(1):65-72. PubMed ID: 12815480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
    Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.
    Montero A; Savani BN; Kurlander R; Read EJ; Leitman SF; Childs R; Solomon SR; Barrett AJ
    Br J Haematol; 2005 Sep; 130(5):733-9. PubMed ID: 16115130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
    Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
    Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.
    Baron F; Schaaf-Lafontaine N; Humblet-Baron S; Meuris N; Castermans E; Baudoux E; Frère P; Bours V; Fillet G; Beguin Y
    Transplantation; 2003 Dec; 76(12):1705-13. PubMed ID: 14688520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
    Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
    Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
    Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
    Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.
    Martin PS; Li S; Nikiforow S; Alyea EP; Antin JH; Armand P; Cutler CS; Ho VT; Kekre N; Koreth J; Luckey CJ; Ritz J; Soiffer RJ
    Haematologica; 2016 Apr; 101(4):499-505. PubMed ID: 26768686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation.
    Dhédin N; Prébet T; De Latour RP; Katsahian S; Kuentz M; Piard N; Réa D; Norol F; Jouet JP; Ribeil JA; Tabrizi R; Rio B; Lioure B; Tiberghien P; Bourhis JH; Sirvent A; Bordigoni P; Blaise D; Michallet M; Vernant JP
    Bone Marrow Transplant; 2012 Dec; 47(12):1564-8. PubMed ID: 22609881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
    Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
    Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
    J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.